Evidence map›Paper›PMID 30461633›Full record

SynthesisMedicine2018

The association between statin use and endometrial cancer survival outcome: A meta-analysis.

Jia Li, Ruijuan Liu, Zhengdi Sun, Shifeng Tang, Lu Wang, Cun Liu, Wenge Zhao, Yan Yao, Changgang Sun

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Statins as Repurposed Drugs in Gynecological Cancer: A Review.International journal of molecular sciences · 2022
    Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jia LiWeifang Medical University.
Ruijuan LiuWeifang Traditional Chinese Hospital, Weifang City.
Zhengdi SunWeifang Traditional Chinese Hospital, Weifang City.
Shifeng TangWeifang Traditional Chinese Hospital, Weifang City.
Lu WangShandong University of Traditional Chinese Medicine, Jinan City, Shandong Province, China.
Cun LiuShandong University of Traditional Chinese Medicine, Jinan City, Shandong Province, China.
Wenge ZhaoWeifang Medical University.
Yan YaoWeifang Medical University.
Changgang SunShandong University of Traditional Chinese Medicine, Jinan City, Shandong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies on the association between statin use and survival outcomes in gynecologic cancers have presented conflicting results. No independent studies to elucidate the association between statin use and survival outcomes of endometrial cancer (EC) have been conducted.

methodsTo gather updated evidence, we carried out an extensive literature search on Medline (PubMed and OvidSP), Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), wanfang data, and Vip network to identify all potential studies on the effect of statins on the prognosis of endometrial carcinoma. The design and quality of all studies were evaluated, and a fixed-effects model was used to calculate pooled hazard ratios (HRs) for overall survival (OS) and disease-specific survival (DSS).

resultsOf the 219 articles screened, 9 articles were eligible, including 8 articles and 1 abstract. A total of 5923 patients with endometrial cancer who used statins were identified. Statin use was related to increased overall survival (HR, 0.80; 95% confidence interval [CI], 0.66-0.95, without significant heterogeneity, I = 52%, P = .080). Statin users also had increased disease-specific survival (HR, 0.69; 95% CI, 0.61-0.79, I = 0.0%).

conclusionStatins are beneficial to the survival outcome of patients with endometrial cancer. The selection of statins as a 1st-line agent seems justified for endometrial carcinoma.

Indexed as

Endometrial NeoplasmsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaObservational Studies as TopicSurvival AnalysisHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID30461633
PMCPMC6393075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.